Volume 6, Supplement 8SupplementThe Evolving Definition of Advanced Prostate CancerJudd W MoulRisk stratificationProstate-specific antigenMetastasisRecurrenceAdvanced prostate cancerEarly hormonal therapyBiochemical recurrenceHormones
Volume 20, Number 2Meeting ReviewsHighlights From the 2018 American Urological Association Annual Meeting, May 18-21, 2018, San Francisco, CABest of the 2018 AUA Annual MeetingAlan W PartinZeyad R Schwen[Rev Urol. 2018;20(2):98–100 doi: 10.3909/riu0806] © 2018 MedReviews®, LLCProstate cancerRisk stratificationActive surveillancempMRI
Volume 22, Number 1Review ArticlesManagement of Low-grade Upper Tract Urothelial Carcinoma: An Unmet NeedManagement ReviewNeal D ShoreJay RamanUpper tract urothelial cancers (UTUC) are frequently managed by radical nephroureterectomy (RNU), a major operative procedure that may entail short-term morbidity and long-term decline in renal function. Kidney-sparing procedures offer a less invasive alternative to RNU for low-risk, low-grade UTUC (LG-UTUC). They are associated with similar disease-specific survival rates and better long-term renal function, albeit with a potentially increased risk of recurrence. Strategies to decrease LG-UTUC recurrence include improved risk stratification and enhanced endoscopic instrumentation. Chemoablation may represent an alternative, innovative kidney-sparing approach for LG-UTUC. [Rev Urol. 2020;22(1):1–8] © 2020 MedReviews®, LLCRisk stratificationUpper tract urothelial cancerRadical nephroureterectomyNephron-sparing procedureLow-grade tumors
Volume 22, Number 4Review ArticlesLow Penetrance Germline Genetic Testing: Role for Risk Stratification in Prostate Cancer Screening and Examples From Clinical PracticeManagement UpdateGerald L AndrioleFranklin GaylisKelly K BreePaul DatoChristopher J KaneA Karim KaderBroad-based prostate-specific antigen (PSA) screening has saved lives but at a substantial human and financial cost. One way of mitigating this harm, while maintaining and possibly improving the benefit, is by focusing screening efforts on men at higher risk. With age, race, and family history as the only risk factors, many men lack any reliable data to inform their prostate cancer (PCa) screening decisions. Complexities including history of previous negative biopsies, interpretation of negative and/or equivocal mpMRI findings, and patient comorbidities further compound the already complicated decisions surrounding PCa screening and early detection. The authors present cases that provide real-world examples of how a single nucleotide polymorphism–based test can provide patients and providers with personalized PCa risk assessments and allow for development of improved risk-stratified screening regimens. [Rev Urol. 2020;22(4):152–158] © 2021 MedReviews®, LLCProstate cancer screeningRisk stratificationSomatic DNA testGermline DNA testsSingle nucleotide polymorphism DNA test